Resistance and viral subtypes: How important are the differences and why do they occur?

Current Opinion in HIV and AIDS

Volumn 2, Issue 2, 2007, Pages 94-102

  Brenner, Bluma G ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Drug resistance; HIV; Subtype diversity

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRITIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; EPIDEMIC; GENE SEQUENCE; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIAL DIVERSITY; MONOTHERAPY; OUTCOME ASSESSMENT; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VIRUS CLASSIFICATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS TYPING;

EID: 34250667082     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32801682e2     Document Type: Review

References (88)

1. UNAIDS/WHO. Report on the global AIDS epidemic. May 2006. Available at: http://unaids.org. [Accessed November 2006] This website gives important information on evolving trends in the HIV-1 epidemic. It is noteworthy that non-B subtypes are not as yet discussed.
2. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature. Science 2000; 288:55-56.
3. Leitner T, Sorber B, Daniels M, et al. HIV subtype and circulating form (CRF) reference sequences. Los Alamos National Laboratory; 2005. Available at: http://hiv.lanl.gov. [Accessed November 2006] The Los Alamos reference laboratory has an updated compendium of new HIV sequences, describing the nomenclature and genomic diversity of rapidly expanding non-B subtypes and CRFs. The Recombination Identification Program (http:// hiv.lanl.gov?RIP/RIP submit.html) can be used to assign subtype or show sequence similarity to all the major CRFs.
4. Thomson MM, Najera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic. AIDS Rev 2005; 7:210-224. The role of superinfection and 'geographical recombination hotspots' in the growing diversification of the HIV pandemic is described.
5. Geretti AM. HIV subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1-7. This is another recent review describing the potential clinical impact of viral subtype diversity.
6. Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002; 2:461-471.
7. Salemi M, de Oliveira T, Soares MA, et al. Different epidemic potentials of the HIV-1 B and C subtypes. J Mol Evol 2005; 60:598-605. This molecular epidemiology study shows the rapidity of the shift to subtype C in a Western world setting.
8. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2 (e112):325-337; www. plosmedine.org. This international collaborative team has been established to compile non-B subtype sequences from different geographical regions.
9. Vergne L, Snoeck J, Aghokeng A, et al. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006; 46:53-62. The problems arising from interpretative algorithms are discussed.
10. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-1983.
11. Niama FR, Tour-Kane C, Vidal N, et al. HIV-1 subtypes and recombinants in the Republic of Congo. Infect Genet Evol 2006; 6:337-343. Phylogenetic surveillance at the epicentre of the HIV pandemic shows the diversity of non-B subtypes and CRFs with the notable absence of subtype C.
12. Ndongmo CB, Pieniazek D, Holberg-Petersen M, et al. HIV genetic diversity in cameroon: possible public health importance. AIDS Res Hum Retroviruses 2006; 22:812-816. Another study illustrating subtype diversity at a geographical 'hotspot'.
13. Chohan B, Lavreys L, Rainwater SMJ, Overbaugh J. Evidence for frequent reinfection with human immunodeficiency virus type 1 of different subtype. J Virol 2005; 79:10701-10708. Superinfection and co-infection remain the sources for the ongoing diversification of the HIV epidemic.
14. Saad MD, Shchererbinskaya AM, Nadai Y, et al. Molecular epidemiology of HIV type 1 in the Ukraine: birthplace of an epidemic. AIDS Res Hum Retroviruses 2006; 22:709-714. This study shows the shift in the dynamics towards non-B subtype infections in Europe and Asia.
15. Pérez L, Thomson MM, Bleda MJ, et al. HIV type 1 molecular epidemiology in Cuba: high genetic diversity, frequent mosaicism, and recent expansion of BG intersubtype recombinant forms. AIDS Res Hum Retroviruses 2006; 22:724-733. This study shows the introduction of non-B subtype diversity and CRF mosaics into the Americas.
16. Aggarwalm I, Smith M, Tatt ID, et al. Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom. J Acquir Immune Defic Syndr 2006; 41:201-209. The forward transmission of non-B subtypes from immigrant patient populations is documented.
17. Sides TL, Akinsete O, Henry K, et al. HIV-1 subtype diversity in Minnesota. J Infect Dis 2005; 192:37-45. This is the first study to show the introduction of non-B subtype strains into the heartland of the United States.
18. Akoumada BS, Viel J, Charest H, et al. HIV-1 genetic diversity in antenatal cohort. Can Emerg Infect Dis 2005; 11:1230-1234. The introduction into Quebec of diverse non-B viral subtypes from francophone countries in west and central Africa shows the diversification arising at the epicentre of the HIV-1 epidemic.
19. Rhee SY, Kantor R, Katzenstein DA, et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS 2006; 20:643-651. The Stanford HIV sequence database, established in 2000, is invaluable, allowing users to assess viral sequence subtype, using the HIVdb subtyping tool (RT and protease region) and the Rega subtyping tool. The database includes mutation frequency of pure viral non-B subtypes submitted to their site. Recent advances allow clinicians and researchers to explore intersubtype differences in genotype with treatment correlates.
20. Shafer RW. Rationale and uses of a public HIV drug resistance database. J Infect Dis 2006; 194:S51-S58. This paper explains to clinicians and researchers how to take advantage of the Stanford database.
21. De Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800. The REGA is a subtyping tool accessible in the Stanford database to designate HIV-1 subtypes and CRFs more effectively.
22. Vercauteren J, Vandamme AM. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res 2006; 71:335-342. A good review that lists current interpretative algorithms.
23. Beerenwinkel N, Schmidt B, Walter H, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci U S A 2002; 99:8271-8276.
24. Hirigoyen DL, Cartwright CP. Use of sequence data generated in the Bayer TruGene genotyping assay to recognize and characterize nonsubtype-B human immunodeficiency virus type 1 strains. J Clin Microbiol 2005; 43: 5263-5271.
25. Gifford R, de Oliveira T, Rambout A, et al. Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS 2006; 20:1521-1529. The ability of different subtyping tools in assessing subtype and CRF is discussed.
26. Van Laethem K, Schrooten Y, Dedecker S, et al. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. J Virol Methods 2006; 132:181-186. Alternative sequencing strategies for non-B subtypes are described.
27. Snoeck J, Riva C, Steegen K, et al. Optimization of a genotypic assay applicable to all immunodeficiency virus type 1 protease and reverse transcriptase types. J Virol Methods 2005; 128:47-53.
28. Ribas SG, Heyndrickx L, Ondoa P, et al. Performance evaluation of the two protease sequencing primers of the Trugene HIV-1 genotyping kit. J Virol Methods 2006; 135:137-142. The divergence in the US Food and Drug Administration-approved primers and the alternative primers required for non-B subtype strains is described.
29. Van de Vijver DA, Wensing AMJ, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41:352-360. This elegant study has assessed codon usage among different viral subtypes in an attempt to calculate genetic barrier and predict resistance in different viral subtypes.
30. De Luca A, Cingolani A, Giambennedetto SD, et al. Variable prediction of antiviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187:1934-1943.
31. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Topics HIV Med 2006; 14:125-130. The International AIDS Society - USA group of HIV-1 clinicians and specialists provides one of the most widely accepted listings of major and minor drug resistance mutations.
32. Schinazi RF, Lloyd RM, Ramanathan CS, Taylor EW. Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions. Antimicrobial Agents Chemother 1994; 38:268-274.
33. Turner D, Brenner B, Moisi D, et al. Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 2993-2998.
34. Wainberg MA, Brenner BG, Turner D. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2005; 49:1671-1678.
35. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Current Opin Infect Dis 2006; 19:594-606. This in an important overview summarizing results from clinical studies in geographical regions where multiple non-B strains circulate.
36. Vergne L, Stuyver L, Houtte MV, et al. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006; 39:43-49. The baseline susceptibility of non-B subtype strains from drug-naive individuals is described.
37. Holguin A, Sune C, Hamy F, et al. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 2006; 36:264-271.
38. Bartlett JA, Fath Mj, DeMasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-2064. This study compiled data from 53 clinical trials showing that HAART fails to achieve viral suppression (<50 copies/ml) in 40-60% of individuals harbouring subtype B infections. Drug resistance may be facilitated in resource-poor settings where suboptimal therapies are being intrioduced.
39. Monforte AA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14:499-507.
40. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 36:808-816.
41. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006; 20:41-48. The clinical benefit of new treatment initiatives in Africa is highlighted.
42. Calmy A, Pinoge L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20:1163-1169. The introduction of cost-effective ART strategies is investigated.
43. Bunnell R, Wamai N, Ekwaru JP, et al. Changes in sexual behavior and risk of HIV transmission after two years of antiretroviral therapy and prevention interventions in rural Uganda. Program and abstracts of the XVIth International AIDS Conference. Toronto, Canada. 13-18 August 2006. Abstract MOAC0204.
44. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10:247-254.
45. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399. The DART trial shows that zidovudine/ lamivudine/tenofovir is of clinical benefit. thymidine analogue mutations, M184V and thymidine analogue mutation pathways arise in non-B subtype infections although subtypes have not been substratified.
46. Tuaillon E, Gueudin M, Lemee V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004; 37:1543-1549.
47. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents. J Virol 1997; 71:8893-8898.
48. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
49. Ren J, Bird LE, Chamberlain PP, et al. Structure of HIV-2 reverse transcriptase at 3.35-A resolution and the mechanism of resistance to nonnucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci U S A 2002; 99: 14410-14415.
50. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
51. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET012 randomized trial. Lancet 1999; 354:795-802.
52. Lallemant M, Jourdain G, Le Cœur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228.
53. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after administration of single-dose NVP. J Infect Dis 2005; 192:30-36. The authors combine two major clinical studies to show intersubtype differences in the acquisition of resistance to nevirapine.
54. Eshleman SH, Church JD, Chen S, et al. Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among african women with subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42:518-521. Although resistance arises in mothers, vertical transmission is reduced. This may mask the detection of subtype disparity in early compared with late transmission to infants.
55. Johnson JA, Li J, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23. Introduction of ultrasensitive PCR assays to detect K103N.
56. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42:610-613. Subtype disparities in transmission of K103N are confirmed using ultrasensitive quantitative PCR techniques.
57. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-29. The dynamics of K103N decay is important in establishing drug-resistance treatment correlates.
58. Toni TD, Masquelier B, Lazaro E, et al. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res Hum Retroviruses 2005; 21:1031-1034. CRF02 shows lower rates of nevirapine resistance similar to those reported for subtype A.
59. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002. Another important study evaluating the evolution of drug resistance over time.
60. Hammer S. Single-dose nevirapine and drug resistance: the more you look, the more you find. J Infect Dis 2005; 192:1-3. This article discusses the clinical implications of nevirapine resistance.
61. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: ANRS Study, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193:482-487. There is a lower risk of the acquisition of nevirapine resistance in A and CRF02 infections.
62. Eshleman SH, Jones D, Galovich J, et al. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. AIDS Res Hum Retroviruses 2006; 22:289-293. Baseline low-level phenotypic resistance in subtype A may attenuate the acquisition of K103N. Unpublished observations in our laboratory confirm these findings.
63. Eshleman S, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquire Immune Defic Syndr 2005; 40:24-29. This study is important in describing the potential mechanisms contributing to intersubtype diversity in the acquisition of resistance.
64. Eshleman S, Lie Y, Hoover DR, et al. Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naive Malawian women. J Infect Dis 2006; 193:1512-1515. This study is important in describing the potential mechanisms contributing to intersubtype diversity in the acquisition of resistance.
65. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-F5.
66. Grossman Z, Istomin V, Averbach D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004; 18:909-915.
67. Morris L, Pillay C, Chezzi C, et al. Low frequency of the V106M mutation among HIV-1 subtypeC-infected pregnant women exposed to nevirapine. AIDS 2003; 17:1698-1700.
68. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
69. Ntemgwa M, Brenner BG, Oliveira M, et al. Natural polymorphisms in the HIV-2 protease can accelerate time to development of resistance to protease inhibitors (PIs) (in press). Antimicrob Agents Chemother 2007.
70. Damond F, Brun-Vezinet F, Matheron S, et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005; 43:484-487.
71. Rodes B, Sheldon J, Toro C, et al. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57:709-713. The secondary mutations in HIV-2 appear to facilitate the development of a multi-PI-resistant phenotype.
72. Diallo K, Brenner B, Oliveira M, et al. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob Agents Chemother 2003; 47:2376-2379.
73. Gonzalez LMF, Aguiar RS, Afonso A, et al. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. J Gen Virol 2006; 87:1303-1309. Insertion of primary mutations in subtype B and C recombinant clones demonstrated differential PI resistance phenotypes, as well as a slower reversion in subtype C when compared with subtype B counterparts.
74. Kinomoto M, Appiah-Opong R, Brandful JAM, et al. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis 2005; 41:243-251. This sophisticated study linked reduced PI phenotypic drug susceptibility in naive patients harbouring CRF02 infections to resistance mutations and molecular modeling of structure-function relationships. This paper offers a fascinating computer modeling approach to deduce intersubtype differences.
75. Katzenstein D, Ogden R. Among the devils in the details are protease sequence, susceptibility and structure in CRF02_AG viruses. Clin Infect Dis 2005; 41:252-254. An interesting editorial commentary describing the difficulty in ascribing secondary mutations and polymorphisms in PI resistance.
76. Grossman Z, Paxinos EE, Averback D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48:2159-2165.
77. Doualla-Bell F, Avalos A, Gaolathe T, et al. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrob Agents Chemother 2006; 50:2210-2213. Viral sequences of patients from Botswana and Israel show differences in the frequency of D30N and L90M nelfinavir pathways that may be linked to intrasubtype differences in secondary mutations.
78. Abecasis AB, Deforche K, Snoeck J, et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005; 19:1799-1806.
79. Deforche K, Silander T, Camacho R, et al. Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance (in press). Bioinformatics 2006; 22.
80. Gonzalez LMF, Brindeiro RM, Aguiar RS, et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004; 48:3552-3555.
81. Calazans A, Brindeiro R, Brindeiro P, et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005; 191:1961-1970.
82. Grant RM, Buchbinder S, Cates W, et al. Promote HIV chemoprophylaxis research, don't prevent it. Science 2005; 309:2170-2171.
83. Grant RM, Wainberg MA. Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis 2006; 194:874-876. Non-B subtype diversity may confound microbicide and chemoprophylaxis strategies.
84. Brenner B, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-F13. Subtype C shows a signature sequence leading to the facilitated development of K65R.
85. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C-infected Batswana patients treated with ddI-based regimens (in press). Antimicrob Agents Chemother 2006.
86. Doualla-Bell F, Gaseitsiwe S, Ndungu T, et al. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother 2004; 15:189-200.
87. Gupta RK, Chrystie IL, O'Shea S, et al. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 2005; 19:1916-1919.
88. Wainberg MA. Generic HIV drugs-enlightened policy for global health. N Engl J Med 2005; 352:747-750.